Alpha counters

EP1013 (F1013) is a broad-spectrum caspase selective inhibitor, used in the research of type 1 diabetesIn VivoEP1013 (1, 3, 10 mg/kg) significantly improves marginal islet mass function. Two animals in the 10 mg/kg EP1013 treatment group exhibit

EP1013 (F1013) is a broad-spectrum caspase selective inhibitor, used in the research of type 1 diabetesIn VivoEP1013 (1, 3, 10 mg/kg) significantly improves marginal islet mass function. Two animals in the 10 mg/kg EP1013 treatment group exhibit

EP1013 (F1013) is a broad-spectrum caspase selective inhibitor, used in the research of type 1 diabetesIn VivoEP1013 (1, 3, 10 mg/kg) significantly improves marginal islet mass function. Two animals in the 10 mg/kg EP1013 treatment group exhibit

ERD-308.

ERD-308.

Protein disulfide isomerase (PDI) inhibitor.

product description：PU02, a derivative of 6-MP, is a negative allosteric modulator (NAM) of 5-HT3 receptor with IC50 of 0.36 μM and 0.73 μM in HEK293 cells transfected with human 5-HT3A and 5-HT3AB receptors, respectively.

product description：PU02, a derivative of 6-MP, is a negative allosteric modulator (NAM) of 5-HT3 receptor with IC50 of 0.36 μM and 0.73 μM in HEK293 cells transfected with human 5-HT3A and 5-HT3AB receptors, respectively.

LINALYL ISOBUTYRATE.

KHS-101.

ERD-308 is a highly potent von Hippel-Lindau-based PROTAC degrader of estrogen receptor (ER) for ER positive breast cancer treatment. ERD-308 induces &gt:95% of ER degradation at concentrations as low as 5 nM in both cell lines (DC50 (concentration

ERD-308 is a highly potent von Hippel-Lindau-based PROTAC degrader of estrogen receptor (ER) for ER positive breast cancer treatment. ERD-308 induces &gt:95% of ER degradation at concentrations as low as 5 nM in both cell lines (DC50 (concentration